Platinum-based drugs have maintained their preeminent position in cancer treatment
regimens even four decades after the approval of cisplatin. Although these agents have …

Owing to the unique DNA damaging cytotoxicity, platinum (Pt)-based chemotherapy has
long been the first-line choice for clinical oncology. Unfortunately, Pt drugs are restricted by …

Abstract All chemotherapeutic treatments worldwide (> 50%) use platinum‐based
compounds. Despite their clinical success, an increasing number of platinum drug‐resistant …

Developing nanocarrier systems with sufficient drug loading ability and efficient drug release
behavior in cells is a powerful strategy to maximize therapeutic efficacies and minimize side …

The antioxidant system of tumor cells severely impairs reactive oxygen species (ROS)-
mediated tumor therapy. Despite extensive attempts to attenuate the antioxidant capacity by …

Biocompatible DNA origami nanostructures (DONs) attract significant interest as potential
targeted drug carriers. Their sensitivity to various environmental triggers is beneficial as a …

The use of cisplatin is restricted by systemic toxicity and drug resistance. Supramolecular
nano-drug delivery systems involving drugs as building blocks circumvent these limitations …

SemiSynBio is an emerging topic toward the construction of platforms for next-generation
information processing. Recent research has indicated its promising prospect toward …

To overcome the resistance of cancer cells to platinum-based drugs and effectively suppress
tumor growth, we developed a novel indium (In) agent based on liposomes (Lips). Thus, we …

The development of effective drug delivery system is highly important for targeted tumor
therapy. Over the past few decades, a number of biomaterials have been extensively …